As part of the partnership, Pfizer will make a $20 million investment and have options to license CytoReason’s platform and disease models. The agreement is worth up to $110 million over the next five years, according to the Sept. 20 Pfizer news release.
Pfizer has used CytoReason’s platform to research over 20 diseases.
“We’re pleased to expand our strategic collaboration with CytoReason,” Pfizer’s chief scientific officer and president Mikael Dolsten said. “We look forward to continuing our work with the company’s leading scientists and to leveraging its cutting-edge platform. CytoReason’s biological data allows us to gain deeper insight into the best drug development pathways for patients, resulting in more informed decisions that are timely and cost-effective.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
